Fenofibrate Has Beneficial Effects on Lipid Profile But Has No Effect on Glucose Metabolism in Type 2 Diabetic Patients with Hyperlipidemia: A Randomized, Double-Blinded, Placebo-Controlled Trial

Ou Horng-Yih; Yu Eugene Hsin; Hsiao Shu-Hwa; Lin Chia-Yin; Wu Ta-Jen

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Fenofibrate Has Beneficial Effects on Lipid Profile But Has No Effect on Glucose Metabolism in Type 2 Diabetic Patients with Hyperlipidemia: A Randomized, Double-Blinded, Placebo-Controlled Trial

Author(s):

Ou Horng-Yih¹,

Yu Eugene Hsin¹,

Hsiao Shu-Hwa¹,

Lin Chia-Yin¹,

Wu Ta-Jen^2,*

1Department of Internal Medicinea University Hospital, Taiwan

2National Cheng Kung University Hospital, [email protected], Taiwan

International Journal of Endocrinology and Metabolism:Vol. 3, issue 4; 184-192

Published online:Oct 31, 2005

Article type:Research Article

Received:Jan 01, 2005

Accepted:Nov 01, 2005

How to Cite:Horng-Yih O, Eugene Hsin Y, Shu-Hwa H, Chia-Yin L, Ta-Jen W. Fenofibrate Has Beneficial Effects on Lipid Profile But Has No Effect on Glucose Metabolism in Type 2 Diabetic Patients with Hyperlipidemia: A Randomized, Double-Blinded, Placebo-Controlled Trial. Int J Endocrinol Metab. 2005;3(4):. doi:

Abstract

Hypolipidemic agent fenofibrate has recently been demonstrated to improve carbohydrate metabolism in animal and cell models. The purpose of this study was to determine its clinical effects on glycemic control and the relationship with its hypolipidemic action in type 2 diabetic patients with hyperlipidemia. Materials and Methods: Forty-eight type 2 diabetic patients with hyperlipidemia were recruited from the Endocrine Division’s outpatient clinic of a tertiary-care university-affiliated centre and randomly assigned micronised fenofibrate 200mg daily or placebo in a double-blinded, placebo-controlled study for three months. A total of 44 patients completed the study. Main outcome measured were changes from the baseline in fasting and postprandial lipid and glycemic variables. Results: Treatment with micronised fenofibrate resulted in a significant decrease in fasting (3.81 ± 1.86 to 1.90 ± 0.77 mmol/L, p< 0.0001) and postprandial triglyceride (5.36±2.640 to 2.30±1.33 mmol/L, p< 0.0001), total cholesterol (6.18±1.17 to 5.23±0.97 mmol/L, p<0.0001) and non-HDL cholesterol (5.09±1.12 to 3.96±1.11 mmol/L, p<0.0001). After treatment the placebo group showed no significant changes in serum lipid levels. Both groups did not alter in fasting and postprandial plasma glucose, mean HbA1c, fasting insulin, QUICKI index and proinsulin-to-insulin ratio. Conclusion: Micronised fenofibrate significantly improved both fasting and postprandial lipid profiles, but did not affect glycemic variables, insulin resistance, and β cell function in patients with type 2 diabetes.

Keywords

Fenofibrate

Type 2 diabetes mellitus

Insulin resistance

Proinsulin-to-insulin ratio

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 6 days ago
Scopus by Title: 0
Last Update: 6 days ago
Scopus by Title (Ref): 0
Last Update: 6 days ago
CrossRef: 0
Last Update: 3 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Ou Horng-Yih:[PubMed][Scholar]
Yu Eugene Hsin:[PubMed][Scholar]
Hsiao Shu-Hwa:[PubMed][Scholar]
Lin Chia-Yin:[PubMed][Scholar]
Wu Ta-Jen:[PubMed][Scholar]

Research Institute for Endocrine Sciences

Outlines

Fenofibrate Has Beneficial Effects on Lipid Profile But Has No Effect on Glucose Metabolism in Type 2 Diabetic Patients with Hyperlipidemia: A Randomized, Double-Blinded, Placebo-Controlled Trial

Abstract

Full Text

Last Update: 6 days ago

Last Update: 6 days ago

Last Update: 6 days ago

Last Update: 3 days ago